Why the study?
Gasdermin D (GSDMD) plays an essential role in pyroptosis, but whether it participates in myocardial ischaemia/reperfusion injury remains poorly understood.
Does GSDMD deficiency reduce infarct size and improve cardiac function in mice with myocardial ischaemia/reperfusion injury?
Does GSDMD deficiency reduce infarct size and improve cardiac function in mice with myocardial ischaemia/reperfusion injury?
GSDMD deficiency reduces infarct size and preserves cardiac function after myocardial ischemia/reperfusion injury in mice by regulating pyroptosis.
Answers are grounded in this paper and cite their sources.
GSDMD targeting may mitigate ischemia/reperfusion injury; hypothesis-generating in mice and leaves open clinical translation.
Background: Gasdermin D (GSDMD) plays an essential role in the pathway of pyroptosis. However, whether GSDMD participates in myocardial ischaemia/reperfusion injury (MI/RI) remains poorly understood. Methods: mice and wild type (WT) mice were induced MI/RI, followed by cardiac ultrasound and histological analysis. Results: mice showed reduced infarct size (25.45 ± 3.07% versus 36.47 ± 3.72%), improved left ventricular ejection fraction (37.71 ± 1.81% versus 29.44 ± 2.28%) and left ventricular fractional shortening (18.01 ± 0.97% versus 13.62 ± 1.15%) as well as attenuated pathological damage after I/R injury, along with reduced levels of proinflammatory cytokines and decreased infiltration of neutrophils. Conclusions: Our study revealed that GSDMD deficiency significantly alleviated the inflammatory response by regulating pyroptosis, reduced the infarct size and preserved cardiac function after MI/RI, thus providing a potential strategy for the treatment of myocardial reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: